選択的エストロゲン受容体調節薬 selective estrogen receptor modulators
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 選択的エストロゲン受容体モジュレーターの作用機序 mechanisms of action of selective estrogen receptor modulators
- 2. 骨粗鬆症の予防および治療のための選択的エストロゲン受容体調節剤 selective estrogen receptor modulators for prevention and treatment of osteoporosis
- 3. 乳癌予防のための選択的エストロゲン受容体調節因子およびアロマターゼ阻害剤 selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention
- 4. 転移性ホルモン受容体陽性乳癌に対する治療アプローチ：内分泌療法 treatment approach to metastatic hormone receptor positive breast cancer endocrine therapy
- 5. 閉経後の女性における骨粗鬆症のマネージメントの概要 overview of the management of osteoporosis in postmenopausal women
English Journal
- Anti-aromatase effect of resveratrol and melatonin on hormonal positive breast cancer cells co-cultured with breast adipose fibroblasts.
- Chottanapund S1, Van Duursen MB2, Navasumrit P3, Hunsonti P4, Timtavorn S4, Ruchirawat M3, Van den Berg M2.
- Toxicology in vitro : an international journal published in association with BIBRA.Toxicol In Vitro.2014 Oct;28(7):1215-21. doi: 10.1016/j.tiv.2014.05.015. Epub 2014 Jun 12.
- Targeting the estrogen pathway has been proven effective in the treatment for estrogen receptor positive breast cancer. There are currently two common groups of anti-estrogenic compounds used in the clinic; Selective Estrogen Receptor Modulators (SERMs, e.g. tamoxifen) and Selective Estrogen Enzyme
- PMID 24929094
- Emerging strategies to overcome resistance to endocrine therapy for breast cancer.
- Ziauddin MF1, Hua D, Tang SC.
- Cancer metastasis reviews.Cancer Metastasis Rev.2014 Sep;33(2-3):791-807. doi: 10.1007/s10555-014-9504-6.
- Endocrine therapy of breast cancer is perhaps the oldest form of effective and well-tolerated targeted cancer systemic treatment, in both the adjuvant and metastatic disease settings. The most commonly used endocrine therapy agents are selective estrogen receptor modulators, aromatase inhibitors, an
- PMID 24944077
- Sex differences in Parkinson's disease and other movement disorders.
- Smith KM1, Dahodwala N2.
- Experimental neurology.Exp Neurol.2014 Sep;259C:44-56. doi: 10.1016/j.expneurol.2014.03.010. Epub 2014 Mar 28.
- Movement disorders including Parkinson's disease (PD), Huntington's disease (HD), chorea, tics, and Tourette's syndrome (TS) display sex differences in disease susceptibility, disease pathogenesis, and clinical presentation. PD is more common in males than in females. Epidemiologic studies suggest t
- PMID 24681088
Japanese Journal
- 骨質からみた骨吸収抑制剤の使い分け : 骨質劣化型骨粗鬆症に対する使い分け (特集 骨粗鬆症の臨床最前線) -- (治療薬,特に骨吸収抑制剤の使い分け)
- 木田 吉城,斎藤 充,丸毛 啓史
- Bone joint nerve : BJN 1(2), 325-330, 2011-07
- NAID 40019219282
- ビスフォスフォネートとSERMの使い分け (特集 骨粗鬆症の臨床最前線) -- (治療薬,特に骨吸収抑制剤の使い分け)
- 岩本 潤
- Bone joint nerve : BJN 1(2), 313-323, 2011-07
- NAID 40019219247
Related Links
- Selective estrogen receptor modulators (SERMs) are a class of compounds that act on the estrogen receptor. A characteristic that distinguishes these substances from pure receptor agonists and antagonists is that their action is different in ...
- 5 Jun 2012 ... Selective estrogen receptor modulators, called SERMs for short, block the effects of estrogen in the breast tissue. SERMs work by sitting in the estrogen receptors in breast cells. If a SERM is in the estrogen receptor, there is no ...
Related Pictures
★リンクテーブル★
| リンク元 | 「選択的エストロゲン受容体調節薬」「selective estrogen-receptor modulators」 |
| 関連記事 | 「SERM」「SER」 |
「選択的エストロゲン受容体調節薬」
- 英
- selective estrogen-receptor modulator, selective estrogen-receptor modulators SERMs
- 関
- エストロゲン受容体、エストロゲン